CAS NO: | 147526-32-7 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Pitavastatin Calcium (NK-104 hemicalcium) is a potenthydroxymethylglutaryl-CoA (HMG-CoA) reductaseinhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibitscholesterolsynthesis from acetic acid with anIC50of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects[1][2][3][8]. | ||||||||||||||||
IC50& Target | HMG-CoA Reductase[1] | ||||||||||||||||
体外研究 (In Vitro) | Pitavastatin Calcium inhibits the growth of a panel of ovarian cancer cells, including those considered most likely to represent HGSOC, grown as a monolayers (IC50 = 0.4-5 μM) or as spheroids (IC50=0.6-4 μM)[3]. Western Blot Analysis[3]
| ||||||||||||||||
体内研究 (In Vivo) | Pitavastatin Calcium (59 mg/kg; p.o.; twice daily for 28 days) causes significant tumour regression[3].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 440.49 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C25H23Ca0.5FNO4 | ||||||||||||||||
CAS 号 | 147526-32-7 | ||||||||||||||||
中文名称 | 匹伐他汀钙 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 50 mg/mL(113.51 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|